Lawsuit Alert: Investors who lost money with shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) should contact the Shareholders Foundation

An investor, who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), filed a lawsuit over alleged violations of Federal Securities Laws by Marinus Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2024. NASDAQ: MRNS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Radnor, PA based Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.

On April 15, 2024, Marinus Pharmaceuticals, Inc announced that "an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis."

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) declined from $11.16 erhsare on December 28, 2023, to as low $1.27 per share on May 20, 2024.

The plaintiff claims that between March 17, 2021 and May 7, 2024, the defendants made materially false and/or misleading statements and/or failed to disclose that defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial, that defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times

Those who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.